{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:21:23Z","timestamp":1757629283877,"version":"3.44.0"},"reference-count":29,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a frequent systemic inflammatory polyarthritis. In recent years, considerable knowledge has been gained in the treatment and diagnosis field. This review will address RA in general, focusing on the effect of the newest treatment option: janus kinase (JAK) inhibitors. Furthermore, using JAK inhibitors to treat RA in a Danish context will be discussed. In conclusion, JAK inhibitor treatment is an effective treatment for rheumatoid arthritis \u2013 however, potential serious side effects and a high price limit its use.<\/jats:p>","DOI":"10.61409\/v09240651","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:23:24Z","timestamp":1746768204000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of rheumatoid arthritis with janus kinase inhibitors"],"prefix":"10.61409","author":[{"given":"Pernille Holme","family":"Thorhauge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders L\u00f8kke","family":"Ottesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Lomborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Matteo AD, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019-2033. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8","DOI":"10.1016\/S0140-6736(23)01525-8"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Myasoedova E, Matteson EL. Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis. Curr Opin Rheumatol. 2024;36(3):203-208. https:\/\/doi.org\/10.1097\/BOR.0000000000001007","DOI":"10.1097\/BOR.0000000000001007"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Wolfe F, Cathey MA, Roberts FK. The latex test revisited. Arthritis Rheum. 1991;34(8):951-60. https:\/\/doi.org\/10.1002\/art.1780340804","DOI":"10.1002\/art.1780340804"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Whiting PF, Smidt N, Sterne JA et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010;152(7):456-64;W155-66. https:\/\/doi.org\/10.7326\/0003-4819-152-7-201004060-00010","DOI":"10.7326\/0003-4819-152-7-201004060-00010"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Di Matteo A, Mankia K, Azukizawa M, Wakefield RJ. The role of musculoskeletal ultrasound in the rheumatoid arthritis continuum. Curr Rheumatol Rep. 2020;22(8):41. https:\/\/doi.org\/10.1007\/s11926-020-00911-w","DOI":"10.1007\/s11926-020-00911-w"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Colebatch AN, Edwards CJ, \u00d8stergaard M et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):804-14. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203158","DOI":"10.1136\/annrheumdis-2012-203158"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Haavardsholm EA, Aga AB, Olsen IC et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ. 2016;354:i4205. https:\/\/doi.org\/10.1136\/10.1136\/bmj.i4205","DOI":"10.1136\/bmj.i4205"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Hemminki K, Li X, Sundquist J, Sundquist K. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum. 2009;60(3):661-8. https:\/\/doi.org\/10.1002\/art.24328","DOI":"10.1002\/art.24328"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360-1372. https:\/\/doi.org\/10.1001\/jama.2018.13103","DOI":"10.1001\/jama.2018.13103"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. https:\/\/doi.org\/10.1136\/ard-2022-223356","DOI":"10.1136\/ard-2022-223356"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Choy EHS, Smith C, Dor\u00e9 CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford). 2005;44(11):1414-21. https:\/\/doi.org\/10.1093\/rheumatology\/kei031","DOI":"10.1093\/rheumatology\/kei031"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947-55. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202220","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"ref12","unstructured":"Which TNF inhibitor for rheumatoid arthritis? Med Lett Drugs Ther. 2010;52(1338):38-9."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898-908. https:\/\/doi.org\/10.1001\/2012.jama.10857","DOI":"10.1001\/2012.jama.10857"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1","DOI":"10.1038\/s41392-021-00791-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Benucci M, Bernardini P, Coccia C et al. JAK inhibitors and autoimmune rheumatic diseases. Autoimmun Rev. 2023;22(4):103276. https:\/\/doi.org\/10.1016\/j.autrev.2023.103276","DOI":"10.1016\/j.autrev.2023.103276"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Zeng X, Zhao D, Radominski SC et al. Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. Int J Rheum Dis. 2021;24(12):1530-1539. https:\/\/doi.org\/10.1111\/1756-185X.14235","DOI":"10.1111\/1756-185X.14235"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Westhovens R, Rigby WFC, van der Heijde D et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80(6):727-738. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219213","DOI":"10.1136\/annrheumdis-2020-219213"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Van Vollenhoven R, Takeuchi T, Pangan AL et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72(10):1607-1620. https:\/\/doi.org\/10.1002\/art.41384","DOI":"10.1002\/art.41384"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H et al. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25(4):514-21. https:\/\/doi.org\/10.3109\/14397595.2014.995875","DOI":"10.3109\/14397595.2014.995875"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Smolen JS, Pangan AL, Emery P et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303-2311. https:\/\/doi.org\/10.1016\/S0140-6736(19)30419-2","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Kremer JM, Cohen S, Wilkinson BE et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64(4):970-81. https:\/\/doi.org\/10.1002\/art.33419","DOI":"10.1002\/art.33419"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Fleischmann R, Schiff M, van der Heijde D et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506-517. https:\/\/doi.org\/10.1002\/art.39953","DOI":"10.1002\/art.39953"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Fleischmann R, Pangan AL, Song IH et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788-800. https:\/\/doi.org\/10.1002\/art.41032","DOI":"10.1002\/art.41032"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Fleischmann R, Mysler E, Hall S et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457-468. https:\/\/doi.org\/10.1016\/S0140-6736(17)31618-5","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Combe B, Kivitz A, Tanaka Y et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80(7):848-858. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219214","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Burmester GR, Kremer JM, Van den Bosch F et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503-12. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","DOI":"10.1056\/NEJMoa2109927"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022;24(1):61. https:\/\/doi.org\/10.1186\/s13075-022-02744-7","DOI":"10.1186\/s13075-022-02744-7"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T13:40:52Z","timestamp":1757511652000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V09240651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":29,"URL":"https:\/\/doi.org\/10.61409\/v09240651","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}